AR-Variant-Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30591516.
- Also identified by DOI 10.1158/1078-0432.CCR-18-3727.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Circulating tumor cells' (CTC) biomarkers may become indicators for selection of therapy. The presence of androgen receptor (AR)-variant-positive CTCs may be markers indicating the need for switching therapy. Methods for AR-variant mRNA isolation from CTCs and confirmation of expression are critical factors needed for these techniques to be clinically applicable.See related article by Tagawa et al., p. 1880.
Medical subject headings
- Neoplastic Cells, Circulating
- Prostatic Neoplasms, Castration-Resistant